Terminated OBSERVATIONAL NCT00515489

Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients

Aggressiveness and Agitation of Acute Psychotic Patients: Influence in Safety and Effectiveness of Risperidone Treatment

Sponsor: Janssen-Cilag, S.A.

Conditions Schizoaffective Disorder Schizophrenia Schizophreniform Disorders

Interventions Risperidone

Updated 6 times since 2017 Last updated: May 18, 2011 Started: Nov 30, 2001 Completion: Aug 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to the achievement of minimum required sample size and new changes in local regulations.

Other terminated trials from Janssen-Cilag, S.A.

More terminations from Janssen-Cilag, S.A.

Other Schizoaffective Disorder trials with similar outcome

Browse all Schizoaffective Disorder trials

Listed as NCT00515489, this observational or N/A phase trial focuses on Schizoaffective Disorder and Schizophrenia and remains terminated or withdrawn. Sponsored by Janssen-Cilag, S.A., it has been updated 6 times since 2001, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated
Jul 2024 — Sep 2024 [monthly]

Terminated
Jan 2021 — Jul 2024 [monthly]

Terminated
Jun 2018 — Jan 2021 [monthly]

Terminated
Apr 2018 — Jun 2018 [monthly]

Terminated

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Terminated NA

First recorded

Nov 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag, S.A.

Data source: Janssen-Cilag, S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.